The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine
Abstract
Buprenorphine was not used widely in clinical practice over many years, mainly due to analgesic potency and clinical safety concerns based on misinterpreted animal data. Contrary to previous concerns, however, no analgesic ceiling effect and no antagonism of combined pure μ‐opioid receptor agonists is seen within the therapeutic dose range. In recent studies, buprenorphine could be effectively and safely combined with full μ‐agonists, and switching between buprenorphine and another opioid provided comparable pain relief based on equianalgesic doses. Moreover, buprenorphine exerts an antihyperalgesic effect, which is due—at least in part—to antagonistic activity at κ‐opioid receptors. Buprenorphine pharmacokinetics are not altered by advanced age or renal dysfunction. In addition, the risk of respiratory depression is lower than with other opioids including morphine, hydromorphone, methadone and fentanyl. Unlike morphine and fentanyl, there is no immunosuppressive activity with buprenorphine at therapeutic analgesic doses. Transdermal buprenorphine has significantly improved the clinical use of the drug, providing continuous buprenorphine release for up to 96h. In clinical trials, patients receiving transdermal buprenorphine experienced significantly greater pain relief, better sleep, and a reduced need for rescue therapy, compared to placebo. Large‐scale post‐marketing studies have confirmed the effectiveness of transdermal buprenorphine in treating moderate‐to‐severe cancer and non‐cancer pain including neuropathic syndromes. Finally, the comparably low incidence of CNS adverse events and constipation, and the possibility of use in severe renal dysfunction without a need for dose adjustment make buprenorphine well suited for chronic pain management in at‐risk patients, such as diabetics, elderly or renally impaired individuals including those requiring haemodialysis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jasinski, D. R. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770280111012 · Cited by 782
Clinical pharmacology of buprenorphine: Ceiling effects at high doses
Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J., & Bigelow, G. E. (1994) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1994.71 · Cited by 773
Buprenorphine suppresses heroin use by heroin addicts
Mello, N. K., & Mendelson, J. H. (1980) · Science · doi:10.1126/science.7352279 · Cited by 298
Buprenorphine: Considerations for Pain Management
Johnson, R. E., Fudala, P. J., & Payne, R. (2005) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2004.07.005 · Cited by 290
Acute administration of buprenorphine in humans: partial agonist and blockade effects.
Walsh, S. L., Preston, K. L., Bigelow, G. E., & Stitzer, M. L. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10510-7 · Cited by 283
Cited by
Guidance on the management of pain in older people
(2013) · Age and Ageing · doi:10.1093/ageing/afs200 · Cited by 727
Hser, Y., Saxon, A. J., Huang, D., Hasson, A., Thomas, C., Hillhouse, M., Jacobs, P., Teruya, C., McLaughlin, P., Wiest, K., et al. (2014) · Addiction · doi:10.1111/add.12333 · Cited by 455
Buprenorphine and Buprenorphine/Naloxone Diversion, Misuse, and Illicit Use: An International Review
A. Yokell, M., D. Zaller, N., C. Green, T., & D. Rich, J. (2011) · Current Drug Abuse Reviewse · doi:10.2174/1874473711104010028 · Cited by 398
Gillis, A., Gondin, A. B., Kliewer, A., Sanchez, J., Lim, H. D., Alamein, C., Manandhar, P., Santiago, M., Fritzwanker, S., Schmiedel, F., et al. (2020) · Science Signaling · doi:10.1126/scisignal.aaz3140 · Cited by 336
Retention of patients in opioid substitution treatment: A systematic review
O’Connor, A. M., Cousins, G., Durand, L., Barry, J., & Boland, F. (2020) · PLOS ONE · doi:10.1371/journal.pone.0232086 · Cited by 298
Metadata
- Authors
- Kress, H. G.
- Venue
- European Journal of Pain
- Publisher
- Wiley
- Published
- 2009-03
- Volume
- 13
- Issue
- 3
- Pages
- 219-230
- ISSN
- 1090-3801 (ISSN-L)
- 1532-2149
- OpenAlex
- W2094878682
- Cited by
- 238
- References
- 5
- FWCI
- 19.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. https://app.cochat.ai/papers/10.1016/j.ejpain.2008.04.011
- The paper
- Kress, H. G. (2009). Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. European Journal of Pain. https://doi.org/10.1016/j.ejpain.2008.04.011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.